Live Breaking News & Updates on Locally Advanced Cervical Cancer

1. Progression-free survival at 24 months was higher in the pembrolizumab versus placebo-controlled group. 2. The pembrolizumab-chemoradiotherapy group reported slightly higher rates of grade 3 or higher adverse events compared to the placebo-chemoradiotherapy group. Evidence Rating Level: 1 (Excellent) Study Rundown: Pembrolizumab has demonstrated efficacy in advanced cervical cancer, prompting an investigation into its potential ....

Rating Level , Response Evaluation Criteria , Solid Tumours , Metastatic Cervical , Between Jun , Cervical Cancer , Gynecologic Oncology , Locally Advanced Cervical Cancer , Chronic Disease ,